TScan Therapeutics, Inc.

TCRX · Nasdaq · United States

Share price · TCRX

$0.15-0.68 (-82.01%) 3M

close as of 2026-11-18 · 24h delayed · vol 657K (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when TCRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 8 Oct 2026-17.6%

    Nothing announced by TCRX that day or the session before.

  2. 2 Sep 2026-42.8%
  3. 19 Aug 2026-9.1%
  4. 9 Jul 2026-15.9%

    Nothing announced by TCRX that day or the session before.

  5. 8 Jul 2026+17.8%

    Nothing announced by TCRX that day or the session before.

  6. 1 Jul 2026+9.2%

    Nothing announced by TCRX that day or the session before.

  7. 26 Jun 2026+15.3%

    Nothing announced by TCRX that day or the session before.

  8. 22 Jun 2026-6.0%
  9. 16 Jun 2026-10.8%

    Nothing announced by TCRX that day or the session before.

  10. 21 Apr 2026-11.2%

    Nothing announced by TCRX that day or the session before.

Share of unusual movement by asset

For each asset, the share of TCRX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
TSC-101
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—32%
Sessions with no dated event—67%

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 3
HA-2 (minor histocompatibility antigen)Cell therapy
Hematologic Malignancies
Phase 1
HA-1 minor histocompatibility antigen (HLA-A*02:01)Cell therapy
Hematologic Malignancies

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
June 2029 (1)
TSC-101Phase 3AML, MDS
Est. primary completion 2029-06 · NCT07702578 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0.6M$25M$78M$33M-$27M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$1.1M$23M$105M$30M-$28M operating cash flowreport ↗
2026-Q1$1.0M$22M$133M$29M-$24M operating cash flowreport ↗
2025-Q3$2.5M$32M$175M+ $15M short-term inv.$36M-$32M operating cash flowreport ↗
2025-Q2$3.1M$33M$174M+ $49M short-term inv.$37M-$33M operating cash flowreport ↗
2025-Q1$2.2M$30M$159M+ $98M short-term inv.$34M-$38M operating cash flowreport ↗
2024-Q3$1.1M$26M$138M+ $138M short-term inv.$30M-$28M operating cash flowreport ↗
2024-Q2$0.5M$27M$247M+ $56M short-term inv.$32M-$26M operating cash flowreport ↗
2024-Q1$0.6M$25M$146M+ $22M short-term inv.$30M-$29M operating cash flowreport ↗
2023-Q3$3.9M$23M$160M+ $60M short-term inv.$23M$8.0M operating cash flowreport ↗
2023-Q2$3.1M$21M$214M$24M-$22M operating cash flowreport ↗
2023-Q1$6.8M$22M$101M$23M-$24M operating cash flowreport ↗
2022-Q3$3.4M$15M$142M$16M-$17M operating cash flowreport ↗
2022-Q2$4.1M$14M$131M$15M-$13M operating cash flowreport ↗
2022-Q1$3.0M$15M$146M$16M-$20M operating cash flowreport ↗
2021-Q3$2.4M$14M$183M$16M-$14M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$10M$114M$157M$32M-$135M operating cash flowreport ↗

TScan Therapeutics reported full-year 2025 revenue of $10.33M, up 266.3% YoY, with R&D spend of $114.15M, up 6.3% YoY. Cash and equivalents stood at $157.44M, and the company reported a net loss of $129.77M.

TScan highlighted positive updated data from the ALLOHA Phase 1 heme trial, completed enrollment in Cohort C using its commercial-ready manufacturing process, and received FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 targeting CD45. The company plans to share initial Cohort C data and launch a pivotal TSC-101 trial in the second quarter of 2026, initiate a Phase 1 study of the TSC-102 candidates in the second half of 2026, and discontinued its PLEXI-T solid tumor trial. Management expects existing cash to fund operations into the second half of 2027.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$2.8M$107M$184M+ $111M short-term inv.$32M-$111M operating cash flowreport ↗
2023-FY$21M$88M$138M+ $59M short-term inv.$22M-$61M operating cash flowreport ↗
2022-FY$14M$60M$125M$17M-$67M operating cash flowreport ↗
2021-FY$10M$45M$166M$12M-$49M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 3 purchases ($146K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-01ZDRAVESKI ZORAN · See RemarksAward / grant300,000——Form 4
2026-10-01MacBeath Gavin · director, Chief Executive OfficerAward / grant1,000,000——Form 4
2026-05-20Klencke Barbara · directorAward / grant (derivative)67,000——Form 4
2026-05-20Dorton Katina · directorAward / grant (derivative)67,000——Form 4
2026-05-20Gruia Gabriela · directorAward / grant (derivative)67,000——Form 4
2026-05-20Nicholson Garry A · directorAward / grant (derivative)67,000——Form 4
2026-05-20Woods Keith · directorAward / grant (derivative)67,000——Form 4
2026-05-20BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN · director; director; director; director; director; directorAward / grant (derivative)67,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 60 reporting institutions held 32.5M shares ($32.2M).

#InstitutionSharesValue
1Lynx1 Capital Management LP8,019,148$8.1M
2BVF INC/IL5,564,290$5.6M
3BAKER BROS. ADVISORS LP2,784,792$2.8M
4VANGUARD CAPITAL MANAGEMENT LLC2,154,256$2.2M
5BlackRock, Inc.1,840,952$1.9M
6MILLENNIUM MANAGEMENT LLC1,460,285$1.5M
7RENAISSANCE TECHNOLOGIES LLC1,364,783$1.4M
8Deer Management Co. LLC1,245,504$1.3M
9TWO SIGMA INVESTMENTS, LP1,209,009$1.2M
10Aberdeen Group plc918,020$927K
11JACOBS LEVY EQUITY MANAGEMENT, INC808,356$816K
12DC Funds, LP630,000$630K
13GEODE CAPITAL MANAGEMENT, LLC616,952$623K
14D. E. Shaw & Co., Inc.319,587$323K
15CITADEL ADVISORS LLC318,411$322K